Progressive cytopenia, development of MDS and increased percentage of bone marrow blasts, abnormal karyotype (3q+, −7,/7q, complex karyotype), RUNX1, and biallelic TP53 mutations are factors that identify risk patients and support the early indication of HSCT in IBMF (1, 6). Here, TP53 is linked to myelodysplastic syndrome.